Acquired pure red cell aplasia: updated review of treatment (Q24652253)

British Journal of Haematology

17 November 2019

immunosuppressive drug

1 reference

26 October 2020

Kenichi Sawada

1

0 references

Naohito Fujishima

series ordinal

2

0 references

Makoto Hirokawa

series ordinal

3

0 references

language of work or name

English

0 references

publication date

August 2008

0 references

1 August 2008

5 references

6 March 2019

13 November 2019

17 November 2019

20 November 2019

26 October 2020

5 references

6 March 2019

13 November 2019

17 November 2019

20 November 2019

26 October 2020

142

0 references

issue

4

0 references

page(s)

505-14

0 references

copyright license

Creative Commons Attribution

5 references

6 March 2019

13 November 2019

17 November 2019

20 November 2019

26 October 2020

0 references

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Current concepts in the pathophysiology and treatment of aplastic anemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Clinical features of large granular lymphocyte leukemia

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Large Granular Lymphocyte Leukemia

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Laboratory findings and clinical courses of 33 patients with granular lymphocyte-proliferative disorders

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple options

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Anti-erythropoietin antibodies and pure red cell aplasia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Aplastic anemia and pure red cell aplasia associated with large granular lymphocyte leukemia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

The CD52 antigen and development of the CAMPATH antibodies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

The effect of treatment with Campath-1H in patients with autoimmune cytopenias

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

28 September 2017

Pure red cell aplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Parvovirus B19 infection causing red cell aplasia in renal transplantation on tacrolimus.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Long-term immunologic effects of thymectomy in patients with myasthenia gravis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Clonal diseases of large granular lymphocytes.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Effects of cyclophosphamide on the development of malignancy and on long‐term survival of patients with rheumatoid arthritis a 20‐year followup study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Studies on red cell aplasia. I. Demonstration of a plasma inhibitor to heme synthesis and an antibody to erythroblast nuclei

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine. A follow-up study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Large granular lymphocyte leukemia. Report of 38 cases and review of the literature

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Pure red cell aplasia: response to therapy with anti-thymocyte globulin

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Granular lymphocyte proliferative disorders: report of 12 cases and review of the literature.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Phenotypic and genotypic analysis of mononuclear cells from patients with Felty's syndrome

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Therapy of pure red cell aplasia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Pure red cell aplasia: review of treatment and proposal for a treatment strategy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Treatment of childhood autoimmune haemolytic anaemia with rituximab

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Acquired pure red cell aplasia in Japan

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Cytotoxic immunosuppressive drug treatment strategy in pure red cell aplasia.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Pure red cell aplasia (PRCA): Response of three patients of cyclophosphamide and/or antilymphocyte globulin (ALG) and demonstration of two types of serum IgG inhibitors to erythropoiesis

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

HLA‐DR4 predicts haematological response to cyclosporine in T‐large granular lymphocyte lymphoproliferative disorders

30 May 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2008.07216.X

Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2008.07216.X

Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2008.07216.X

Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2008.07216.X

Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2008.07216.X

Wegener Granulomatosis: An Analysis of 158 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2008.07216.X

Successful high-titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab-combined chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2008.07216.X

Persistent parvovirus B19 related anemia of seven years' duration in an HIV-infected patient: complete remission associated with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2008.07216.X

Anti-CD20 monoclonal antibody rituximab for the treatment of B-cell chronic lymphocytic leukemia-associated pure red cell aplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2008.07216.X

An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2008.07216.X

Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti‐CD52 monoclonal antibody alemtuzumab (Campath‐1H)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2008.07216.X

Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2008.07216.X

Initial predictors of development of pure red cell aplasia in myasthenia gravis after thymectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2008.07216.X

Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2008.07216.X

Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2008.07216.X

Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2008.07216.X

Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Treatment of pure red-cell aplasia and aplastic anaemia with ciclosporin: long-term clinical effects.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592349

Treatment of refractory pure red cell aplasia with cyclosporine A: disappearance of IgG inhibitor associated with clinical response

28 November 2018

1 reference

12 December 2020

Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan

1 reference

12 December 2020

Low-dose methotrexate for the treatment of patients with large granular lymphocyte leukemia associated with rheumatoid arthritis

1 reference

12 December 2020

Cyclophosphamide therapy for pure red cell aplasia associated with granular lymphocyte-proliferative disorders

1 reference

12 December 2020

Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins

1 reference

12 December 2020

Neutropenia associated with T-cell large granular lymphocyte leukemia: long-term response to cyclosporine therapy despite persistence of abnormal cells

1 reference

12 December 2020

Cyclosporine A used as a single drug in the treatment of pure red cell aplasia associated with thymoma

1 reference

12 December 2020

The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditions

1 reference

12 December 2020

Induction of NK activity in large granular lymphocyte leukemia: activation with anti-CD3 monoclonal antibody and interleukin 2

1 reference

12 December 2020

Successful response to rituximab in a patient with pure red cell aplasia complicating chronic lymphocytic leukaemia

1 reference

12 December 2020

Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia

1 reference

12 December 2020

The pathophysiology of pure red cell aplasia: implications for therapy

1 reference

12 December 2020

A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group

1 reference

12 December 2020

Large granular lymphocyte/natural killer cell proliferative disease: clinical and laboratory heterogeneity

1 reference

12 December 2020

The Role of Thymectomy in Red Cell Aplasia

1 reference

12 December 2020

Successful treatment of pure red-cell aplasia with cyclosporin

1 reference

12 December 2020

Studies on pure red cell aplasia. Maintenance therapy with immunosuppressive drugs

1 reference

12 December 2020

Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients

1 reference

12 December 2020

Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab

1 reference

12 December 2020

Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease

1 reference

12 December 2020

Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance?

1 reference

12 December 2020

Lymphocyte subsets associated with T cell receptor β‐chain gene rearrangement in patients with rheumatoid arthritis and neutropenia

1 reference

12 December 2020

Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate

1 reference

12 December 2020

Management of persistent B19 parvovirus infection in AIDS

1 reference

12 December 2020

10.1111/J.1365-2141.2008.07216.X

Identifiers

DOI

1 reference

1 reference

1 reference

PubMed publication ID

18510682

1 reference